Webinar: Inflammatory Disease Modeling for Preclinical Studies
Our webinar “Inflammatory Disease Modeling for Preclinical Studies" was live at 1:00 PM EST on February 15th, 2023. In this webinar, we Provided a brief overview…
Read more
PepTalk 2023
Join us at booth #401 at PepTalk 2023 from January 16-20 in San Diego, CA! Whether you need humanized models, PK/PD services, or antibody discovery…
Read more
Biocytogen and Hansoh Pharma Announce an Antibody License Agreement
BEIJING, China, and Shanghai, China, January 3, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus…
Read more
Biocytogen Launches RenNano® Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery
Beijing, China, December 30, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano®. RenNano® is the…
Read more
7th Tumor Models for Immuno-Oncology Summit
Join us at the 7th Tumor Models for Immuno-Oncology Summit in San Francisco, CA from January 24 - 26, 2023! We will be presenting "Next-Generation…
Read more
Biocytogen BDL Team to Participate in the 41st Annual JPM Healthcare Conference, the Biotech Showcase and BIO Partnering at JPM
Biocytogen (HKEX: 02315) will attend the upcoming 41st J.P. Morgan (JPM) Healthcare Conference week, and participate in several satellite conferences, including the Biotech Showcase and…
Read more
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
BEIJING, China, December 19, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New…
Read more
American Society for Cell Biology 2022
Join us at booth #704 at Cell Bio 2022 from December 3-7 in Washington, DC, hosted by American Society for Cell Biology (ASCB)! Whether you need…
Read more
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BEIJING, China, November 28, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option…
Read more
Antibody Engineering & Therapeutics 2022
Join us at booth #608 at Antibody Engineering & Therapeutics 2022 in San Diego, CA, December 4 - 8! Learn more about our antibody discovery…
Read more